5:36 PM
Nov 06, 2013
 |  BC Extra  |  Politics & Policy

NIH won't exercise march-in for Norvir patents

NIH denied an October 2012 petition from several not-for-profits requesting that the agency exercise its march-in authority under the Bayh-Dole Act for six patents covering HIV drug Norvir ritonavir from AbbVie Inc. (NYSE:ABBV). Under the...

Read the full 161 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >